FDA Cybersecurity Design Controls: Key Requirements
Post Summary
Medical devices connected to networks face critical medical device security risks. To address this, the FDA mandates cybersecurity design controls to ensure safety and functionality. These controls are guided by Section 524B of the FD&C Act and include:
- Software Bill of Materials (SBOM): Lists all software components to track vulnerabilities.
- Secure Product Development Framework (SPDF): Embeds security throughout the device lifecycle.
- Authentication and Cryptography: Protects device access and data integrity.
- Resiliency and Updates: Ensures devices withstand attacks and receive timely patches.
As of April 2026, compliance is critical for premarket submissions to avoid rejection. Manufacturers must integrate these controls into their Quality Management Systems (QMS) and provide detailed documentation, including threat modeling and risk assessments. The goal is clear: safeguard patient safety by designing secure devices from the start.
FDA Cybersecurity Design Controls: Three Essential Categories and Requirements
FDA cybersecurity requirements: What is surprising and new in 2026?
sbb-itb-535baee
Core FDA Cybersecurity Requirements
The FDA has established specific cybersecurity standards for medical devices, rooted in Section 524B of the FD&C Act and the Secure Product Development Framework (SPDF). These guidelines set clear expectations for both premarket approval and ongoing security measures.
Section 524B of the FD&C Act: Key Provisions
Introduced through the Consolidated Appropriations Act of 2023, Section 524B of the Federal Food, Drug, and Cosmetic Act became effective on March 29, 2023. This law reshaped how the FDA regulates cybersecurity for medical devices, introducing enforceable standards for devices with internet connectivity or cybersecurity vulnerabilities [5].
Mike McGuire from Black Duck summarizes the scope of this regulation:
Section 524B mandates 'reasonable assurance of cybersecurity' for software-enabled medical devices, and requires Software Bills of Materials (SBOMs), secure product development frameworks (SPDFs), and postmarket vulnerability monitoring [3].
Manufacturers must adhere to several critical requirements under this section:
- Software Bill of Materials (SBOM): A machine-readable SBOM must list all software components, including commercial, open-source, and off-the-shelf software [3][6].
- Postmarket Vulnerability Management: A detailed plan must outline how vulnerabilities will be monitored, identified, and addressed promptly [3].
- Timely Software Updates: Manufacturers are required to provide updates and patches to resolve security issues that could compromise device functionality or patient safety [3].
As of October 1, 2023, the FDA's "Refuse to Accept" policy has lapsed, meaning all premarket submissions must now fully comply with Section 524B. Noncompliance can result in submission refusals [3][4][7].
In addition to these legislative mandates, manufacturers are expected to adopt proactive development practices to counter evolving cybersecurity threats.
Secure Product Development Framework (SPDF)
Section 524B(b) also mandates the implementation of a Secure Product Development Framework (SPDF), ensuring cybersecurity is embedded into a device's lifecycle from the outset [7].
This framework shifts the focus from reactive fixes to proactive, lifecycle-wide security measures [6]. It requires integrating cybersecurity into all phases of development - design, creation, and maintenance [7].
The FDA suggests using NIST Special Publication 800-218 (Secure Software Development Framework - SSDF) as a foundation for creating an SPDF that aligns with regulatory standards [3]. By adhering to these guidelines, manufacturers can meet FDA expectations while following established industry practices.
To ensure compliance, manufacturers should incorporate SPDF processes into their broader Quality Management System (QMS). This integration not only satisfies regulatory requirements but also reinforces patient safety. The importance of this alignment is underscored by the FDA's updated premarket submission process: as of October 1, 2023, all 510(k) submissions must use the eSTAR electronic template, which includes a Cybersecurity section. Incomplete submissions may face Technical Screening holds [7].
The urgency of these measures is further highlighted by Gartner's forecast that 45% of organizations worldwide will experience software supply chain attacks by the end of 2025 [3].
Required Cybersecurity Design Control Categories
To meet FDA expectations, manufacturers need to integrate cybersecurity measures directly into the design of medical devices. These measures should address vulnerabilities from the very beginning, rather than being added later. The FDA highlights three essential categories of cybersecurity controls that manufacturers must implement to protect medical devices effectively.
Authentication and Authorization Controls
These controls are designed to regulate who can access a device and what actions they can perform. They play a critical role in preventing unauthorized individuals from controlling device functions or accessing sensitive patient information.
Manufacturers must assign unique credentials to every device and function. Using shared passwords or reusing keys across devices poses severe security risks. Modern protocols like TLS 1.3 and advanced Public Key Infrastructure (PKI) ensure mutual authentication between users and devices [8]. The FDA also requires manufacturers to provide detailed documentation on how credentials - such as passwords, keys, and tokens - are created, stored, transferred, and maintained throughout the device's lifecycle [9].
In addition, strong cryptographic methods are necessary to maintain the device's integrity and protect its operations.
Cryptography and Integrity Controls
Cryptography is a cornerstone of device security, ensuring that data remains authentic, intact, and confidential [8]. As Medcrypt notes:
Cryptography isn't just about encryption - it's about establishing trust [8].
Integrity controls safeguard data at rest, data in transit, software binaries, and running software from being altered [9]. The FDA considers weak cryptographic measures as "reasonably foreseeable failure modes" that must be addressed during the design phase [9]. To counteract these risks, manufacturers should adopt measures like secure boot mechanisms with firmware signing and trusted boot processes to prevent tampering or unauthorized code execution [8]. Device configurations should be verified at startup, with systems defaulting to a safe failure mode if tampering is detected [9]. Cryptographic practices must align with NIST standards, particularly FIPS 140-3 and SP 800-131A. Incorporating hardware-based security, such as FIPS 140-3 validated Hardware Security Modules (HSMs), is recommended for critical operations [8].
While authentication and cryptography protect devices from unauthorized access and data breaches, resilience is key to handling cyber threats.
Resiliency and Updatability Controls
Medical devices must be capable of withstanding cyberattacks and supporting secure updates throughout their use. The FDA stresses that cybersecurity must be embedded into the design process from the outset [9].
Resiliency controls enable devices to detect attacks, maintain essential functions, and recover safely. Meanwhile, updatability controls ensure manufacturers can roll out patches and fixes without compromising the device's integrity or patient safety. Robust key lifecycle management - encompassing generation, storage, rotation, revocation, and re-provisioning - is critical [8]. This also aligns with the postmarket vulnerability management requirements outlined in Section 524B, enabling manufacturers to respond quickly to new threats.
Premarket Documentation and Testing Requirements
Manufacturers are required to submit comprehensive premarket documentation to demonstrate that their devices can withstand cybersecurity threats, as outlined in Section 524B. The FDA's guidance from June 2025, titled "Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions," provides the benchmark for these submissions [2]. This documentation must include details about threat modeling and testing processes, showing how vulnerabilities are identified and addressed.
Threat Modeling and Risk Assessments
Threat modeling is a critical step in identifying vulnerabilities during the design phase. Manufacturers need to document all device risks and the strategies used to address them [10]. Risk assessments should clearly link potential vulnerabilities to specific mitigation measures. For instance, if a device connects to a hospital network, the threat model must address risks such as unauthorized access, data breaches, and malware attacks. Submissions must include a summary of identified cybersecurity risks and the methods used to mitigate them [10][2].
Verification, Validation, and Testing
Testing is essential to confirm that the device's cybersecurity measures function as intended. These activities must align with Quality Management System (QMS) considerations to ensure consistency during FDA evaluation. The FDA mandates documentation proving that devices are "sufficiently resilient to cybersecurity threats" [1]. This involves verification and validation testing to ensure:
- Authentication mechanisms work as intended.
- Cryptographic controls safeguard data integrity.
- Resiliency features effectively respond to attacks.
The FDA highlights the importance of these efforts:
These recommendations are intended to promote consistency, facilitate efficient premarket review, and help ensure that marketed medical devices are sufficiently resilient to cybersecurity threats [2].
Premarket Submission Documentation
Premarket submissions must include detailed documentation covering both device design and labeling [1]. This should demonstrate compliance with Section 524B and address three key categories of cybersecurity controls: authentication and authorization, cryptography and integrity, and resiliency and updatability [1]. Manufacturers are expected to align their documentation with QMS frameworks to streamline the review process and meet regulatory standards [1][2]. This approach ensures that cybersecurity considerations are integrated into the design process from the very beginning, rather than being added later.
Integrating Cybersecurity with Quality Systems
The updated Quality Management System Regulation (QMSR), set to take effect on February 2, 2026, brings FDA's 21 CFR 820.30 into alignment with ISO 13485:2016. A key feature of this update is the integration of cybersecurity as a core element of quality management. This change highlights the growing recognition that cybersecurity is closely tied to software quality and directly influences patient safety. By embedding cybersecurity into every stage - from design to post-market activities - manufacturers can better connect technical safeguards with overall quality management practices.
Failing to address design-control issues early can lead to costly consequences. These deficiencies account for a rising number of Form 483 observations, Warning Letters, and medical device recalls. Late-stage fixes are significantly more expensive, costing between 10 and 100 times more than early-stage adjustments, with expenses ranging from $3 million to over $600 million[11].
Aligning Cybersecurity with Quality Management Systems
Incorporating cybersecurity into Quality Management Systems (QMS) is now a critical step for manufacturers preparing premarket submissions. This integration demonstrates a device's resilience during FDA reviews. Building on the FDA's established cybersecurity requirements, manufacturers are expected to embed these controls throughout the entire design process.
Every aspect of 21 CFR 820.30 must now include cybersecurity considerations. For instance, Design Inputs (820.30(c)) require manufacturers to document security needs - such as encryption standards, authentication protocols, and regulatory requirements - as formal specifications. These inputs are often verified through rigorous processes, which can take up to 30% of the project timeline for complex devices[11]. Similarly, Design Verification (820.30(f)) and Design Validation (820.30(g)) demand thorough testing to confirm security measures function as intended. Testing typically involves lab prototypes or production-equivalent devices. Notably, Design Validation was the most cited FDA deficiency in FY 2020, with 38 violations recorded[11].
Additionally, all security patches and software updates must follow the Design Changes (820.30(i)) process, ensuring proper documentation, verification, and validation before implementation. Meanwhile, the Design History File (DHF) (820.30(j)) must compile all cybersecurity-related documentation, including threat models, risk assessments, and test results, to demonstrate compliance during FDA inspections[11].
Engaging cybersecurity specialists and manufacturing teams early in the design review process is critical. This collaboration helps identify and address potential vulnerabilities early, reducing costs and ensuring compliance with regulatory standards while prioritizing patient safety[11].
Using Censinet RiskOps™ for FDA Compliance
Healthcare organizations and device manufacturers face mounting pressure to meet FDA cybersecurity requirements, especially given the sheer volume of data they handle. For example, a 300-bed hospital generates a staggering 1.37 TB of data every single day [6]. Managing this data while tracking risks across medical devices, third-party vendors, and clinical applications is no small feat. This is where Censinet RiskOps™ steps in, offering a centralized platform tailored to healthcare's unique cybersecurity challenges. It complements cybersecurity design controls by simplifying and streamlining risk management processes.
Streamlining Cybersecurity Risk Management
Censinet RiskOps™ builds upon integrated Quality Management Systems to centralize and automate risk management processes. With its tools, manufacturers and healthcare delivery organizations can perform threat modeling and risk assessments with ease. Manual workflows become a thing of the past as the platform automates these assessments, offering a single command center to visualize risks across devices, supply chains, and third-party vendors.
For manufacturers working on FDA submissions, Censinet RiskOps™ facilitates early collaboration between cybersecurity and manufacturing teams. This proactive approach minimizes the likelihood of expensive fixes down the line. The platform also supports continuous postmarket vulnerability monitoring [5], a critical requirement under Section 524B of the FD&C Act. By automating processes, it ensures compliance with both premarket and postmarket FDA requirements throughout a device’s lifecycle.
Simplifying Compliance Documentation and Benchmarking
Premarket submissions to the FDA demand detailed cybersecurity documentation, including a Software Bill of Materials (SBOM) [4][6]. Censinet RiskOps™ simplifies this process by automatically compiling risk data, test results, and security controls into formats aligned with FDA standards.
The platform also allows manufacturers to benchmark their security posture against FDA requirements. This proves especially useful when demonstrating adherence to the Secure Product Development Framework (SPDF) and maintaining documentation for the Design History File (DHF). By consolidating all cybersecurity-related evidence in one centralized location, organizations can significantly cut down on the time and effort needed to prepare for FDA inspections and premarket reviews.
Conclusion
FDA cybersecurity design controls play a critical role in creating medical devices that are both safe and secure. As Global MedTech Expert Ran Chen aptly puts it:
Quality cannot be inspected into a finished product - it must be designed in from the beginning [12].
This idea aligns with the FDA's Quality Management System Regulation (QMSR), which, starting February 2, 2026, incorporates ISO 13485:2016 by reference.
The financial case for strong design controls is undeniable. Making design changes late in development can be 10 to 100 times more expensive than addressing issues during the requirements phase. Alarmingly, over half of all FDA medical device recalls are linked to design control weaknesses. Routine recalls can cost millions, while systemic design flaws can result in losses exceeding $600 million [12].
By integrating cybersecurity into the design process - through features like authentication controls, cryptography, threat modeling, and ongoing risk assessments - manufacturers can protect patients, ensure compliance, and safeguard their financial health. These measures, guided by Section 524B and the Secure Product Development Framework (SPDF), establish a proactive approach to managing risks throughout a product’s lifecycle. Beyond risk mitigation, such controls also pave the way for smoother regulatory compliance.
Tools like Censinet RiskOps™ can simplify this process for manufacturers and healthcare delivery organizations. By centralizing risk management, automating documentation, and enabling continuous postmarket monitoring, these tools turn a potentially daunting task into a manageable, systematic process. This approach strengthens adherence to the regulatory framework while enhancing operational efficiency.
Investing in strong cybersecurity design controls not only protects patients but also offers significant financial returns, with potential ROI ranging from 3 to 10 times the initial investment [12].
FAQs
Which devices does FDA Section 524B apply to?
FDA Section 524B focuses on medical devices that incorporate software, connect to the internet or other networks (either directly or indirectly), and face potential cybersecurity risks. These types of devices are commonly known as "cyber devices."
What must a machine-readable SBOM include?
A machine-readable SBOM (Software Bill of Materials) needs to include critical details such as:
- Supplier information: Identifying the source of each component.
- Component versions: Listing the specific versions of all included software components.
- Dependencies: Mapping out how components rely on each other.
- Timestamps: Indicating when the SBOM was created or updated.
- Vulnerability assessments: Highlighting known security issues within components.
To ensure consistency and compatibility, it’s essential to use established formats like SPDX or CycloneDX. These formats help standardize the way SBOMs are structured and shared.
What evidence should be included in a 510(k) to demonstrate cybersecurity?
A 510(k) submission must contain key evidence such as a cybersecurity management plan, risk assessments, and vulnerability testing results (like penetration testing). It should also include a Software Bill of Materials (SBOM) and detailed documentation outlining strategies for postmarket vulnerability monitoring and mitigation. These components are crucial to show adherence to FDA cybersecurity standards.
